Diligence memo · auto-generated · as of July 2, 2026

Tychon Biosciences LLC

Tychon Biosciences LLC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Tychon Biosciences LLC operates in Biotech / Pharma, based in MINNEAPOLIS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Tychon Biosciences LLC has raised $671K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $471K on 2015-11-02.

Most recent recorded round closed around 2018-10-09.

Valuation (modeled)modeled

Provath models Tychon Biosciences LLC at approximately $10M (range $109K–$116M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.57× the median modeled value of Pre-Seed Biotech / Pharma companies in 2016–2018 (12 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 35 months.

Last raise 7.7 yr ago; this sector typically re-raises about every 15 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.4× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 26% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 34% of those peers.

Closest niche peers: Orbis Biosciences, Inc, Nexion Biosciences Inc, Synereca Pharmaceuticals, Inc., Novome Biotechnologies, Inc., Me Biosciences, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.